Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06360861
Other study ID # 1400-1-233-51589
Secondary ID IR.TUMS.MEDICINE
Status Completed
Phase Phase 1
First received
Last updated
Start date July 23, 2019
Est. completion date March 6, 2024

Study information

Verified date March 2024
Source Tehran University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the safety and of a single dose of IV infusion of placenta derived Mesenchymal Stem Cells (PLMSCs) in patients with secondary progressive Multiple Sclerosis (SPMS) disease. Monitoring will be encompassed baseline assessments and follow-ups over subsequent months, evaluating clinical signs, Expanded Disability Status Scale (EDSS), cytokines, diffusion tensor imaging (DTI), functional MRI (fMRI), cognitive & psychological evaluations, and flow cytometry for B cell markers.


Description:

This open-label phase I study will be conducted in MS Clinic of Sina and Shariati Hospital of Tehran province . In this study, diagnosis and management of MS patients will be performed based on McDonald's criteria and Iran's diagnostic and treatment protocols. The patients will be received a single injection of PLMSCs through the intravenous cannula. The proposed study will assess safety and short efficacy endpoints of PLMSCs administered to 5 patients with SPMS. The primary objective of the trial is freedom from treatment associated adverse events at 1,3 and 6 months' post treatment. Secondary objective will be efficacy as assessed at baseline, at 1,3 and 6 months and will be based on the following: EDSS, cytokines, DTI, fMRI, cognitive & psychological evaluations, and flow cytometry for B cell markers.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date March 6, 2024
Est. primary completion date March 4, 2024
Accepts healthy volunteers No
Gender All
Age group 17 Years to 45 Years
Eligibility Criteria: Inclusion Criteria: - Age between 17-45 years Patients with SPMS . - Must be able to Sign informed consent . - Currently taking Rituximab. - Disease duration of more than 2 and less than 16 years. Exclusion Criteria: - Pregnancy or breastfeeding. - hepatitis B and C, human immunodeficiency virus (HIV), and human T-cell lymphotropic virus (HTLV) disease. - Using cytotoxic agents within 3 months prior to the study. - Severe anemia (hemoglobin< 8 mg/dl), coagulation disorders. - history of malignancy . - liver disorders . - significant cardiac, renal or hepatic failure . - Active or chronic infection. - Life-threatening organ dysfunction. - Unable to give written informed consent . - Current treatment with an investigational therapy.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Allogenic placenta derived mesenchymal stem cells
Allogenic placenta derived mesenchymal stem cells, 3 million cells/kg body weight via intravenous injection.

Locations

Country Name City State
Iran, Islamic Republic of Tehran University of Medical Sciences,Tehran, Iran Tehran

Sponsors (1)

Lead Sponsor Collaborator
Tehran University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

References & Publications (2)

Ebrahimi-Barough S, Ai J, Payab M, Alavi-Moghadam S, Shokati A, Aghayan HR, Larijani B, Arjmand B. Standard Operating Procedure for the Good Manufacturing Practice-Compliant Production of Human Endometrial Stem Cells for Multiple Sclerosis. Methods Mol Biol. 2021;2286:199-212. doi: 10.1007/7651_2020_281. — View Citation

Shokati A, Naser Moghadasi A, Nikbakht M, Sahraian MA, Mousavi SA, Ai J. A focus on allogeneic mesenchymal stromal cells as a versatile therapeutic tool for treating multiple sclerosis. Stem Cell Res Ther. 2021 Jul 13;12(1):400. doi: 10.1186/s13287-021-02477-5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with Treatment-Emergent Adverse Events [Safety and Tolerability]. adverse events Up to 6 months
Secondary Number of participants with a change in disability as measured by Expanded Disability Status Scale . Proportion of patients with clinical improvement in EDSS score compared to baseline. EDSS scores range from 0 = no disability to 10 = death due to MS and higher scores mean a worse outcome. Up to 6 months
Secondary Number of participants with a change in cognitive function as measured by the Paced Auditory Serial Addition Test . The minimum score is 0 and maximum score is 60, and higher scores mean a better outcome. Up to 6 months
Secondary Number of participants with a change in cognitive performance as measured by Persian version of minimal assessment of cognitive function in MS battery. Assessment of cognitive function Up to 6 months
Secondary Number of participants with a change in brain connectivity as measured by Functional magnetic resonance imaging . Assessment of brain connectivity Up to 6 months
Secondary Number of participants with a change in white matter integrity as measured by quantitative diffusion tensor imaging . Change from baseline in white matter integrity Up to 6 months
Secondary Number of participants with a change in processing and motor speed as assessed by the Symbol Digit Modalities Test . Change from baseline in processing and motor speed of patients and higher scores mean a better outcome. Up to 6 months
Secondary Number of participants with evaluation of verbal learning and memory deficits as measured by the California Verbal Learning Test second edition . Change from baseline in verbal learning and memory deficits and higher scores mean a better outcome. Up to 6 months
Secondary Proportion of patients with change in CD20 / CD19 B cells surface markers Blood samples will be collected pre and post treatment for immediate or ulterior analysis. Up to 3 months
Secondary Biological Assessments including IL-10, IL-6, IL-17, and TNFa levels of cytokines. Blood samples will be collected pre and post treatment for immediate or ulterior analysis. Up to 3 months
Secondary Proportion of patients with change in T2 lesion volume on brain MRI. Change from baseline in T2 lesion volume. Up to 6 months
Secondary Proportion of patients with change in brain volume on MRI. Change from baseline in brain volume Up to 6 months
Secondary Proportion of patients for assessment of visuospatial learning as measured by the Brief Visuospatial Memory Test-Revised . Change from baseline in visuospatial learning Up to 6 months
Secondary Proportion of patients for assessment of visuospatial ability as measured by Judgment of Line Orientation Test . Change from baseline in visuospatial ability Up to 6 months
Secondary Proportion of patients for evaluation of executive functions as measured by the Delis-Kaplan Executive Function System Sorting and descriptive tests. Change from baseline in executive functions Up to 6 months
Secondary Proportion of patients for measuring verbal fluency as measured by the Controlled Oral Word Association Test . Change from baseline in measuring verbal fluency Up to 6 months
Secondary Proportion of patients for psychological assessment as measured by the validated Persian version of Symptom Checklist-90-Revised . Symptom Checklist-90(SCL-90) is a collection of nine subscales (with 90 items) for evaluation of Somatization, Obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism in the past week. Each item has a 5-point Likert scale and scoring from 0 to 4. SCL-90 Global Severity was calculated by dividing the sum of all subscales scores by 9. Up to 6 months
Secondary Proportion of patients for evaluation of fatigue as measured by was examined by the Persian version of Fatigue Severity Scale . Fatigue Severity Scale(FSS )is a scale with 9 items, which assesses the fatigue severity in the past 2 weeks. Each item has a score from 1 to 7 and total score will be from 9 to 63. Higher FSS score indicates higher fatigue severity. Up to 6 months
Secondary Proportion of patients for assessment of visuospatial ability as measured by the brief visuospatial memory test-revised test. Change from baseline in visuospatial ability Up to 6 months
Secondary Proportion of patients for assessment of visuospatial ability as measured by the California Verbal Learning Test Second Edition test. Change from baseline in visuospatial ability Up to 6 months
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis